|
|
|
| |
 |
|
|
|
推薦指數：
|
|
- 內容介紹
|
Handbook of Therapeutic Antibodies: Technologies, Emerging Developments and Approved Therapeutics
by Dubel, Stefan
3527329021 / 9783527329021
LC class: TP number:
Edition 1 , 2010 , John Wiley & Sons Inc
Antibodies are an essential part of the immune system in vertebrates. Their generation involves a random mutation and rearrangement process and they can be in principle directed against any biological compound. In the last years biotechnological processes have been developed allowing for the selection of any antibody with a specific target and the subsequent large scale production of this antibody.
This most comprehensive reference source for the development, production and therapeutic application of antibodies is now available as a paperback edition. It includes general chapters presenting established technologies and clinical applications, chapters on emerging technologies, new therapeutic concepts, and clinical studies and detailed and specific information about currently approved therapeutic antibodies, including clinical data.
This is a must-have resource for academic researchers and decision makers in the industry, as well as healthcare professionals in the clinic.
Section I: Technologies
Foreword
A Greeting from the Editor
PART 0: INTRODUCTION
Therapeutic Antibodies - From Past to Future
PART I: SELECTING AND SHAPING THE ANTIBODY MOLECULE
Selection strategies I: Monoclonal Antibodies
Selection strategies II: Antibody Phage Display
Selection strategies III: Transgenic Mice
Bioinformatic Tools for Antibody Engineering
Molecular Engineering I: Humanization
Molecular Engineering II: Affinity Maturation
Molecular Engineering III: Fc Engineering
PART II: THE WAY INTO THE CLINIC
Production and Downstream Processing
Pharmaceutical Formulation and Clinical Application
Immunogenicity of Antibody Therapeutics
Regulatory Considerations
Intellectual Property Issues
Section II: Emerging Developments
PART III: BEYOND IGG: MODIFIED ANTIBODIES
Immunoscintigraphy and Radioimmunotherapy
Bispecific Antibodies
Immunotoxins /
Targeted RNases
PART IV: EMERGING CONCEPTS
Automation of Selection and Engineering
Emerging Technologies for Antibody Selection
Emerging Alternative Production Systems
Non-Antibody Scaffolds
Emerging Therapeutic Concepts I: ADEPT
Emerging Therapeutic Concepts II: Nanotechnology
Emerging Therapeutic Concepts III:Cell-bound antibodies
Emerging Therapeutic Concepts IV:Anti-idiotypic Antibodies
PART V: ONGOING CLINICAL STUDIES:
Antibodies in Phase I/II/III: Cancer Therapy
Antibodies in Phase I/II/III: Targeting TNF
Section III: APPROVED THERAPEUTICS
Adalimumab (Humira)
Alemtuzumab (Mabcampath)
Bevacizumab (Avastin)
Cetuximab (Erbitux)
Efalizumab (Raptiva)
Fanolesomab/Technetium99m (Neutrospec)
Gemtuzumab Ozogamicin (Mylotarg)
Infliximab (Remicade)
Muromonab (Orthoclone)
Natalizumab (Tysabri)
Omalizumab (Xolair)
Palivizumab (Synagis)
Rituximab (Rituxan)
Trastuzumab (Herceptin)
Overview: Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab and Votumumab
Yttrium-90 Ibritumomab Tiuxetan (Zevalin)
|
|
|
其他相關書藉
[ 
[ 